N-(2-aminoethyl)-2-(2-(((4αS,7S,7αR,12βS)-4α,9-dihydroxy-3-methyl-2,3,4,4α,5,6,7,7α-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2-oxoethoxy)acetamide | 1443990-86-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: N-(2-aminoethyl)-2-(2-(((4αS,7S,7αR,12βS)-4α,9-dihydroxy-3-methyl-2,3,4,4α,5,6,7,7α-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2-oxoethoxy)acetamide
• 英文别名: 2-[2-[[(4R,4aS,7S,7aR,12bS)-4a,9-dihydroxy-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]amino]-2-oxoethoxy]-N-(2-aminoethyl)acetamide
• CAS: 1443990-86-0
• 化学式: C₂₃H₃₂N₄O₆
• 分子量: 460.53
• InChiKey: HDIRPCCICBUNSF-DRDDYJBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  146
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-(2-aminoethyl)-2-(2-(((4αS,7S,7αR,12βS)-4α,9-dihydroxy-3-methyl-2,3,4,4α,5,6,7,7α-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2-oxoethoxy)acetamide 、 2-(2-(2-(3-((6-methylpyridin-2-yl)ethynyl)phenoxy)ethylamino)-2-oxoethoxy)acetic acid 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.25h， 以60%的产率得到N-((4αS,7S,7αR,12βS)-4α,9-dihydroxy-3-methyl-2,3,4,4α,5,6,7,7α-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)-2-((14-(3-((6-methylpyridin-2-yl)ethynyl)phenoxy)-2,7,11-trioxo-9-oxa-3,6,12-triazatetradecyl)oxy)acetamide
  参考文献：
  名称：

  [EN] ANALGESIC CONJUGATES
  [FR] CONJUGUÉS ANALGÉSIQUES

  摘要：

  该发明提供了一种镇痛共轭物，其中包含与mGluR5拮抗剂连接的mu阿片受体激动剂，并提供了使用这种化合物产生镇痛作用的方法。

  公开号：

  WO2014124317A1
• 作为产物：
  描述：

  2,2-dimethyl-4,9-dioxo-3,11-dioxa-5,8-diazatridecan-13-oic acid 在 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.75h， 生成 N-(2-aminoethyl)-2-(2-(((4αS,7S,7αR,12βS)-4α,9-dihydroxy-3-methyl-2,3,4,4α,5,6,7,7α-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2-oxoethoxy)acetamide
  参考文献：
  名称：

  [EN] ANALGESIC CONJUGATES
  [FR] CONJUGUÉS ANALGÉSIQUES

  摘要：

  该发明提供了一种镇痛共轭物，其中包含与mGluR5拮抗剂连接的mu阿片受体激动剂，并提供了使用这种化合物产生镇痛作用的方法。

  公开号：

  WO2014124317A1

文献信息

• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：UNIV MINNESOTA

  公开号：WO2016138142A1

  公开（公告）日：2016-09-01

  and salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using a compound of formula I.

  其中的盐也被披露。还披露了包括I式化合物的药物组合物，用于制备I式化合物的过程，用于制备I式化合物的有用中间体以及使用I式化合物的治疗方法。
• Induced Association of μ Opioid (MOP) and Type 2 Cholecystokinin (CCK₂) Receptors by Novel Bivalent Ligands
  作者：Yaguo Zheng、Eyup Akgün、Kaleeckal G. Harikumar、Jessika Hopson、Michael D. Powers、Mary M. Lunzer、Laurence J. Miller、Philip S. Portoghese

  DOI：10.1021/jm800174p

  日期：2009.1.22

  between morphine and CCK in the CNS. However, association was induced, as indicated by a positive BRET signal, on exposure of the cells to bivalent ligands containing μ-opioid agonist and CCK2 receptor antagonist pharmacophores linked through spacers containing 16−22 atoms but not with a shorter (9-atom) spacer. These studies demonstrate for the first time that an appropriately designed bivalent ligand

  μ-阿片类药物 (MOP) 和 2 型胆囊收缩素 (CCK 2 ) 受体都存在于中枢神经系统区域，这些区域与疼痛处理的调节有关。我们对共表达 MOP 和 CCK 2受体的COS 细胞进行了生物发光共振能量转移 (BRET) 研究，以确定受体异二聚化是否参与这种调节。这些研究表明不存在组成型或单价配体诱导的异二聚化。因此，MOP 和 CCK 2受体的异二聚化不太可能是吗啡和 CCK 在 CNS 中的相反作用的原因。然而，如阳性 BRET 信号所示，当细胞暴露于含有 μ-阿片类激动剂和 CCK 的二价配体时，会诱导结合2受体拮抗剂药效团通过含有 16-22 个原子的间隔物连接，但不与较短（9 个原子）的间隔物相连。这些研究首次证明适当设计的二价配体能够诱导 G 蛋白偶联受体的结合。在小鼠中使用这些配体进行的阿片类药物耐受性研究表明与 BRET 数据没有相关性的发现与体内MOP 和 CCK 2受体不存在关联是一致的。
• Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid1 (CB₁) Receptors Are Potent Analgesics Devoid of Tolerance
  作者：Morgan Le Naour、Eyup Akgün、Ajay Yekkirala、Mary M. Lunzer、Mike D. Powers、Alexander E. Kalyuzhny、Philip S. Portoghese

  DOI：10.1021/jm4005219

  日期：2013.7.11

  Given that mu opioid (MOP) and canabinoid (CB1) receptors are colocalized in various regions of the central nervous system and have been reported to associate as heteromer (MOP-CB1) in cultured cells, the possibility of functional, endogenous MOP CB1 in nociception and other pharmacologic effects has been raised. As a first step in investigating this possibility, we have synthesized a series of bivalent ligands 1-5 that contain both mu agonist and CB1 antagonist pharmacophores for use as tools to study the functional interaction between MOP and CB1 receptors in vivo. Immunofluorescent studies on HEK293 cells coexpressing both receptors suggested 5 (20-atom spacer) to be the only member of the series that bridges the protomers of the heteromer. Antinociceptive testing in mice revealed 5 to be the most potent member of the series. As neither a mixture of monovalent ligands 9 + 10 nor bivalents 2-5 produced tolerance in mice, MOR-CB1 apparently is not an important target for reducing tolerance.
• Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR₅)
  作者：Eyup Akgün、Muhammad I. Javed、Mary M. Lunzer、Michael D. Powers、Yuk Y. Sham、Yoshikazu Watanabe、Philip S. Portoghese

  DOI：10.1021/acs.jmedchem.5b01245

  日期：2015.11.12

  Chemokine release promotes cross-talk between opioid and chemokine receptors that in part leads to reduced efficacy of morphine in the treatment of chronic pain. On the basis of the possibility that a MOR-CCR5 heteromer is involved in such cross-talk, we have synthesized bivalent ligands (MCC series) that contain mu opioid agonist and CCR5 antagonist pharmacophores linked through homologous spacers (14-24 atoms). When tested on lipopolysaccharide-inflamed mice, a member of the series (MCC22; 3e) with a 22-atom spacer exhibited profound antinociception (i.t. ED50 = 0.0146 pmol/mouse) that was 2000X greater than morphine. Moreover, MCC22 was similar to 3500X more potent than a mixture of mu agonist and CCR5 antagonist monovalent ligands. These data strongly suggest that MCC22 acts by bridging the protomers of a MOR-CCR5 heteromer having a TM5,6 interface. Molecular simulation studies are consistent with such bridging. This study supports the MOR-CCR5 heteromer as a novel target for the treatment of chronic pain.